AtaGenix Laboratories
AtaGenix’s naïve library technology enables rapid antibody discovery with high diversity (up to 10¹⁰ variants) while eliminating the need for animal immunization. Compared to hybridoma technology, our phage display approach reduces turnaround time to 3-4 months and removes the need for further humanization, ensuring efficient and cost-effective therapeutic antibody development.
Rapid Antibody Screening
Select high-affinity antibodies within 3-4 months, twice as fast
Animal-Free & Ethical
No animal immunization, fully human naïve library screening
No Further Humanization Needed
Direct selection of fully human antibodies, reducing costs
Library | Format | Species | Size(Capacity) |
---|---|---|---|
LiAb-SFCOVID-19™ | scFv | Human – COVID-19 recovered donors | 1.35 × 10¹⁰ |
LiAb-SFMAX™ | scFv | Human – 5 ethnic groups, 368 donors | 7.38 × 10¹⁰ |
LiAb-SFAutoimmune™ | scFv | Human – with autoimmune disease | 4.78 × 10⁹ |
LiAb-VHHMAX™ | VHH | Camel, llama, alpaca , 76 donors | 2.71 × 10¹⁰ |
LiAb-SFDab™ | scFv | Dog – 6 breeds,26 donors | 1.52 × 10¹⁰ |
LiAb-SFCab™ | scFv | Cat – 10 breeds,78 donors | 1.67 × 10¹⁰ |
LiAb-SFRab™ | scFv | Rabbit– 5 breeds,64 donors | 2.95 × 10¹⁰ |
LiPep-12 | Peptide 12-mer | / | 1.00 × 10⁹ |
LiPep-7 | Peptide 7-mer | / | 1.00 × 10⁹ |
Example of the **panning (biopanning) protocol** in **Phage Display**: